Brepocitinib for Uveitis
(NEPTUNE Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial allows participants to be on one non-corticosteroid, non-biologic, immunomodulatory therapy, so you may need to adjust your current medications to meet this requirement.
What data supports the effectiveness of the drug Brepocitinib for treating uveitis?
How is the drug Brepocitinib unique for treating uveitis?
What is the purpose of this trial?
This trial will test the safety and effectiveness of a pill called brepocitinib in people with a type of eye inflammation that isn't caused by an infection. The pill works by calming the immune system to reduce swelling and irritation in the eye.
Research Team
Brendan Johnson, PhD
Principal Investigator
SVP, Early Development
Eligibility Criteria
Adults aged 18-74 with active non-infectious uveitis (intermediate, posterior, or panuveitis) can join. They must have certain levels of eye inflammation and may be on one non-corticosteroid treatment. Weight over 40 kg and BMI under 40 are required. Those with isolated anterior uveitis, recent cancers except some skin or localized cancers, high thrombosis risk, active infections, or herpes zoster risk cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive oral brepocitinib for the treatment of non-infectious uveitis
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Brepocitinib
Find a Clinic Near You
Who Is Running the Clinical Trial?
Priovant Therapeutics, Inc.
Lead Sponsor